ライフサイエンスコーパス: eosinophilic

1 etadata further defined 3 of these as highly eosinophilic, 3 as highly neutrophilic, and 2 as highly

2 Grass pollen exposure was associated with eosinophilic airway inflammation 1-2 days after exposure

3 agged 2 single- or double-deficient mice had eosinophilic airway inflammation and a TH2 cell activati

4 rmine whether gammaT supplementation reduces eosinophilic airway inflammation and acute neutrophilic

5 ncy in mice prevented house dust mite-driven eosinophilic airway inflammation and significantly reduc

6 The level of eosinophilic airway inflammation correlates with variati

7 ide (FENO) is a useful noninvasive marker of eosinophilic airway inflammation in asthmatics.

8 The extent to which eosinophilic airway inflammation in severe asthma respon

9 merican subjects were more likely to exhibit eosinophilic airway inflammation than white subjects in

10 3-deficient cDC1s did not develop Th2-driven eosinophilic airway inflammation upon HDM exposure, but

11 required in two different models to amplify eosinophilic airway inflammation via induced expression

12 d OVA induced airway hyperresponsiveness and eosinophilic airway inflammation were both completely di

13 d OVA-induced airway hyperresponsiveness and eosinophilic airway inflammation were both significantly

14 CD11c-Cre mice have a phenotype of increased eosinophilic airway inflammation, allergic sensitization

15 hma phenotype, usually with a severe course, eosinophilic airway inflammation, and increased producti

16 During eosinophilic airway inflammation, approximately 30% of l

17 Signatures associated with eosinophilic airway inflammation, mast cells, and group

18 African American subjects exhibit greater eosinophilic airway inflammation, which might explain th

19 derate asthma and were also characterized by eosinophilic airway inflammation, yet increased producti

20 duced similar airway hyperresponsiveness and eosinophilic airway inflammation.

21 siveness is closely related to the degree of eosinophilic airway inflammation.

22 needed for IL-33-induced ILC2 expansion and eosinophilic airway inflammation.

23 mune responses in the setting of HDM-induced eosinophilic airway inflammation.

24 g depletion was significantly greater during eosinophilic airway inflammation.

25 ted with elevated FeNO, suggesting increased eosinophilic airway inflammation.

26 f exhaled nitric oxide (FeNO) is a marker of eosinophilic airway inflammation.

27 three clinically relevant asthma phenotypes: eosinophilic allergic asthma, eosinophilic nonallergic a

28 wenty-six hospitalized asthma patients (nine eosinophilic allergic; EA, nine noneosinophilic allergic

29 ntial therapeutic target for EoE and related eosinophilic and allergic diseases.

30 ions and that gammaT supplementation reduces eosinophilic and endotoxin (LPS)-induced neutrophilic ai

31 Clca1 (Gob5) and Muc5ac were upregulated in eosinophilic and even more in neutrophilic phenotype.

32 Eosinophilic and mixed neutrophilic/eosinophilic inflamm

33 e dust extracts as adjuvants developed mixed eosinophilic and neutrophilic airway inflammation and ai

34 NP and CRSwNP displayed variable degrees of eosinophilic and neutrophilic inflammation, with a profo

35 ressed ex vivo on blood eosinophils from all eosinophilic and normal individuals studied.

36 ular pathways involved in both patients with eosinophilic and those with noneosinophilic asthma.

37 bacterial markers that discriminate T2-high (eosinophilic) and T2-low (neutrophilic/mixed-inflammatio

38 L-HCCs: large polygonal cells with granular, eosinophilic, and mitochondria-rich cytoplasm, prominent

39 Benralizumab is an anti-eosinophilic, anti-interleukin-5 receptor alpha monoclon

40 ils, and VOCs gave a very good prediction of eosinophilic asthma (area under the receiver operating c

41 sed sputum ANCAs compared with patients with eosinophilic asthma (P = 0.002) and healthy controls (P

42 PA (n = 10, serum ANCA(+)), 19 patients with eosinophilic asthma (prednisone dependent), and 13 healt

43 icacy of mepolizumab in patients with severe eosinophilic asthma (SEA).

44 patients aged 12 years or older with severe eosinophilic asthma and a history of at least two exacer

45 Only CST1 was common to eosinophilic asthma and COPD and was replicated in indep

46 Total serum IgE was increased in eosinophilic asthma and COPD.

47 t basophils may be particularly important in eosinophilic asthma and that sputum basophil assessment

48 phils, proved clinically effective in severe eosinophilic asthma but not in mild asthma.

49 r assess mepolizumab in patients with severe eosinophilic asthma by examining its effect on health-re

50 polizumab, patients with uncontrolled severe eosinophilic asthma experienced clinically significant i

51 blood myeloid DC subsets from patients with eosinophilic asthma have lower LRP-1 expression than cel

52 sive and externally validated test to assess eosinophilic asthma in patients not on OCS.

53 events airway hyperresponsiveness in a mouse eosinophilic asthma model.

54 ophil resolution and could contribute to the eosinophilic asthma phenotype.

55 with anti-IL-5 therapies, many patients have eosinophilic asthma that remains poorly controlled.

56 ncy room visit rates in patients with severe eosinophilic asthma treated with mepolizumab or placebo

57 with sputum IL-1beta protein levels, whereas eosinophilic asthma was associated with an IL-13-induced

58 will allow selection of patients with severe eosinophilic asthma who are most likely to achieve clini

59 research into therapeutics for patients with eosinophilic asthma who do not respond to anti-IL-5 ther

60 th the highest classification performance in eosinophilic asthma with accuracy comparable to that of

61 The proposed prediction model identifies eosinophilic asthma without the need for sputum inductio

62 the majority of these publications relate to eosinophilic asthma, a growing proportion of them focus

63 remodeled asthma, (3) late-onset nonallergic eosinophilic asthma, and (4) late-onset nonallergic none

64 mprovements in HRQOL in patients with severe eosinophilic asthma, and had a safety profile similar to

65 e pathophysiology in stable and exacerbating eosinophilic asthma, and therefore treatment is focused

66 can be classified into 4 unique phenotypes: eosinophilic asthma, neutrophilic asthma, mixed granuloc

67 rs4008366 presented modest association with eosinophilic asthma.

68 nce treatment for patients with uncontrolled eosinophilic asthma.

69 zumab for patients with severe, uncontrolled eosinophilic asthma.

70 ce similar to Fe(NO) or blood eosinophils in eosinophilic asthma.

71 other inflammatory phenotypes, particularly eosinophilic asthma.

72 roves lung function for patients with severe eosinophilic asthma.

73 ompared with placebo in patients with severe eosinophilic asthma.

74 teroids (ICS) are a mainstay of treatment in eosinophilic asthma.

75 ent with mepolizumab in patients with severe eosinophilic asthma.

76 educes exacerbations in patients with severe eosinophilic asthma.

77 to standard of care in patients with severe eosinophilic asthma.

78 to treat patients with severe, uncontrolled, eosinophilic asthma.

79 ng with blood eosinophil levels, asthma, and eosinophilic asthma.

80 argeting of the IL33 pathway specifically in eosinophilic asthma.

81 Neutrophilic, but not eosinophilic, asthmatics display overexpression of IFN-b

82 MPO+ ANCA EGPA is an eosinophilic autoimmune disease sharing certain clinical

83 The levels of IL-8, IL-13 and eosinophilic cationic protein (ECP) were also measured i

84 sal polyp tissues at Week 16 vs baseline for eosinophilic cationic protein (P = 0.008), eotaxin-2 (P

85 ophil degranulation increased, and levels of eosinophilic cationic protein were higher in duodenal fl

86 Two fetal markers were expressed in eosinophilic cells potentially derived from the X-zone t

87 ld patient with severe asthma complicated by eosinophilic chronic rhinosinusitis (ECRS).

88 Pediatric eosinophilic colitis (EC) is a rare disease with a preva

89 EG), eosinophilic gastroenteritis (EGE), and eosinophilic colitis (EC), yet these diseases are barely

90 gation, we asked whether esophagitis with an eosinophilic component is observed in young pigs rendere

91 d, GPTD does not resemble a granulomatous or eosinophilic condition.

92 Eosinophilic COPD may represent an overlap with asthma b

93 lung function or qCT, but were increased in eosinophilic COPD.

94 NERD subjects had elevated sputum eosinophilic count as compared to ATA-CRSwNP and HC (med

95 inflammatory profile characteristic of human eosinophilic CRSwNP.

96 high-grade morphology with abundant granular eosinophilic cytoplasm, resembling mitochondria-rich apo

97 histiocytoid appearance with foamy granular eosinophilic cytoplasm.

98 Eo-MDSC exhibit eosinophilic cytoplasmic granules and express CD11b, the

99 d eosin and Masson trichrome staining showed eosinophilic deposits in subepithelial corneal stroma th

100 lic esophagitis (EoE) is an antigen-mediated eosinophilic disease of the esophagus that involves fibr

101 Interest in eosinophil biology and eosinophilic diseases is increasing, as reflected in a d

102 eosinophil granules are found in tissues in eosinophilic diseases, including asthma.

103 ces in our understanding of eosinophilia and eosinophilic disorders (excluding asthma) published in t

104 the basis for the use of glucocorticoids in eosinophilic disorders, and it has intrigued clinicians

105 gnosis, treatment, and pathogenesis of other eosinophilic disorders, most notably eosinophilic esopha

106 ar and persist in tissues from patients with eosinophilic disorders, such as asthma, allergic reactio

107 he mechanism of action of glucocorticoids in eosinophilic disorders, with implications for the study

108 epresents a potential therapeutic target for eosinophilic disorders.

109 onsidered first-line therapy in a variety of eosinophilic disorders.

110 sSiglec-8) levels in normal donors (NDs) and eosinophilic donors (EOs) and assess the efficacy of ant

111 who had symptomatic eosinophilic gastritis, eosinophilic duodenitis, or both conditions in a 1:1:1 r

112 Eosinophilic esophagitis (EoE) afflicts both children an

113 ely mimic the Th2 and inflammatory milieu of eosinophilic esophagitis (EoE) and assessed alterations

114 Patients with eosinophilic esophagitis (EoE) and extremely high esopha

115 Fibrostenosis, the most serious eosinophilic esophagitis (EoE) complication, is mediated

116 A high prevalence of eosinophilic esophagitis (EoE) has been preliminarily re

117 Thus far, eosinophilic esophagitis (EoE) has received the most foc

118 Topical steroid treatments for eosinophilic esophagitis (EoE) include swallowed flutica

119 Eosinophilic esophagitis (EoE) is a chronic allergic dis

120 Eosinophilic esophagitis (EoE) is a chronic and increasi

121 Eosinophilic esophagitis (EoE) is a chronic antigen-medi

122 Eosinophilic esophagitis (EoE) is a chronic inflammatory

123 Eosinophilic esophagitis (EoE) is a chronic inflammatory

124 Eosinophilic esophagitis (EoE) is a chronic inflammatory

125 Eosinophilic esophagitis (EoE) is a chronic, esophageal,

126 Eosinophilic esophagitis (EoE) is a chronic, food antige

127 Eosinophilic esophagitis (EoE) is a chronic, immune/anti

128 Eosinophilic esophagitis (EoE) is a new disease.

129 Eosinophilic esophagitis (EoE) is a recently described d

130 Eosinophilic esophagitis (EoE) is a relatively new disea

131 Eosinophilic esophagitis (EoE) is an allergen-mediated i

132 Eosinophilic esophagitis (EoE) is an antigen-mediated eo

133 Eosinophilic esophagitis (EoE) is an emerging tissue-spe

134 Eosinophilic esophagitis (EoE) is an emerging, chronic,

135 Eosinophilic esophagitis (EoE) is an eosinophil-rich, T(

136 Although eosinophilic esophagitis (EoE) is associated with certai

137 The pathology of eosinophilic esophagitis (EoE) is characterized by eosin

138 Treatment failure in eosinophilic esophagitis (EoE) is common.

139 The incidence of eosinophilic esophagitis (EoE) is greater in male than f

140 The prevalence of Eosinophilic esophagitis (EoE) is increasing, a severe c

141 ACKGROUND & AIMS: Pharmacologic treatment of eosinophilic esophagitis (EoE) is limited to off-label u

142 g studies have observed an increased risk of eosinophilic esophagitis (EoE) mostly among first-degree

143 Diagnostic evaluation of eosinophilic esophagitis (EoE) remains difficult, partic

144 ng eosinophilic tissue inflammation, such as eosinophilic esophagitis (EoE), a chronic inflammatory d

145 ve been recognized as a primary treatment of eosinophilic esophagitis (EoE), an allergic inflammatory

146 L-22, and IL-23) of patients with achalasia, eosinophilic esophagitis (EoE), and gastroesophageal ref

147 advances in the pathologic understanding of eosinophilic esophagitis (EoE), as of yet, no single age

148 orrelate with tissue pathology during active eosinophilic esophagitis (EoE), providing additional evi

149 ure are major comorbidities in patients with eosinophilic esophagitis (EoE).

150 g gastroesophageal reflux disease (GERD) and eosinophilic esophagitis (EoE).

151 using on a tissue-specific allergic disease, eosinophilic esophagitis (EoE).

152 factor in many allergic diseases, including eosinophilic esophagitis (EoE).

153 ds are recommended as first-line therapy for eosinophilic esophagitis (EoE).

154 f empiric elimination diets in patients with eosinophilic esophagitis (EoE).

155 elimination from the diets of patients with eosinophilic esophagitis (EoE).

156 Dysphagia is the main symptom of adult eosinophilic esophagitis (EoE).

157 e of type 2 cytokines in the pathogenesis of eosinophilic esophagitis (EoE); however, heterogeneity i

158 Eosinophilic esophagitis can now be treated with biologi

159 herapy) and 20 controls, stored in the Swiss Eosinophilic Esophagitis Database (SEED) and Biobank, we

160 s recapitulated the majority of the clinical Eosinophilic Esophagitis Diagnostic Profile (EDP) on flu

161 Eosinophilic esophagitis experts were surveyed to estima

162 Eosinophilic esophagitis has been reported as a complica

163 Treatment of eosinophilic esophagitis has progressed from elemental f

164 Patients with eosinophilic esophagitis have increased numbers of mucos

165 a useful large animal model for the study of eosinophilic esophagitis in humans.

166 Eosinophilic esophagitis is an emerging disease that is

167 wth factor beta production and signaling, to eosinophilic esophagitis pathophysiology.

168 We also discuss eosinophilic esophagitis subtypes, factors associated wi

169 bservational study was continued, a study of eosinophilic esophagitis was initiated, and new therapeu

170 patients with eosinophilic skin diseases or eosinophilic esophagitis were used for in vivo analyses.

171 ergic rhinitis, allergic conjunctivitis, and eosinophilic esophagitis), suggesting both cutaneous and

172 n an allergic inflammatory tissue focused on eosinophilic esophagitis, a prototypic, chronic, allergi

173 elial dysregulation in asthma, food allergy, eosinophilic esophagitis, and allergic rhinosinusitis.

174 in asthma, rhinitis, chronic rhinosinusitis, eosinophilic esophagitis, food allergy, and atopic derma

175 Eosinophilic esophagitis-like esophageal inflammation wa

176 f other eosinophilic disorders, most notably eosinophilic esophagitis.

177 e dysregulated in atopic disorders including eosinophilic esophagitis.

178 increasingly prescribed for the treatment of eosinophilic esophagitis.

179 esonide tablet licensed for the treatment of eosinophilic esophagitis.

180 Eosinophilic gastritis (EG) is a clinicopathologic disor

181 ts of the gastrointestinal tract and include eosinophilic gastritis (EG), eosinophilic gastroenteriti

182 Eosinophilic gastritis and duodenitis are characterized

183 otential in animal models as a treatment for eosinophilic gastritis and duodenitis.

184 In patients with eosinophilic gastritis or duodenitis, AK002 reduced gast

185 randomly assigned adults who had symptomatic eosinophilic gastritis, eosinophilic duodenitis, or both

186 y (OIT), but there are only a few reports of eosinophilic gastroenteritis (EGE) occurring after OIT.

187 act and include eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic col

188 hout EG were enrolled across 9 Consortium of Eosinophilic Gastrointestinal Disease Researchers-associ

189 m 10 sites associated with the Consortium of Eosinophilic Gastrointestinal Disease Researchers.

190 mmation due to inflammatory bowel disease or eosinophilic gastrointestinal disease showed the least b

191 Eosinophilic gastrointestinal diseases (EGIDs) are rare

192 evelopment of such a process that focuses on eosinophilic gastrointestinal diseases.

193 angiitis (GPA), microscopic polyangiitis and eosinophilic GPA (EGPA), are defined according to clinic

194 inflamed human tissues, we often find intact eosinophilic granules, but not eosinophils themselves.

195 versus 19% of placebo-treated patients with eosinophilic granulomatosis with polyangiitis (EGPA) ach

196 The immunologic mechanisms promoting eosinophilic granulomatosis with polyangiitis (EGPA) are

197 Eosinophilic granulomatosis with polyangiitis (EGPA) is

198 Eosinophilic granulomatosis with polyangiitis (eGPA) is

199 multiple mononeuritis (MM) in patients with eosinophilic granulomatosis with polyangiitis (EGPA).

200 Eosinophilic granulomatosis with polyangiitis is an eosi

201 sculitis, Crohn's disease, Behcet's disease, eosinophilic granulomatosis with polyangiitis, and immun

202 In participants with eosinophilic granulomatosis with polyangiitis, mepolizum

203 associated with EM were hypersensitivity and eosinophilic granulomatosis with polyangiitis, which acc

204 cut point to define subjects with either an eosinophilic (>/=2%) or noneosinophilic (<2%) inflammato

205 s revealed significant levels of oesophageal eosinophilic infiltration (P < .05) in 4/6 of these anim

206 a, histologic features of disease (including eosinophilic infiltration and a marker of type 2 inflamm

207 their small intestine villi and had reduced eosinophilic infiltration as compared to the untreated b

208 Eosinophilic infiltration has long been a histologic hal

209 6 of these animals, with two also displaying eosinophilic infiltration in the stomach.

210 gested that Hsp70 is critically required for eosinophilic infiltration, collagen accumulation, and Th

211 Lungs from these mice show strong eosinophilic infiltration, excessive Th2 polarization, m

212 tological and endoscopic findings, including eosinophilic infiltration.

213 Biopsies from the esophagus showed an eosinophilic inflammation (65 eosinophils/HPF).

214 ce ICS treatment response in the presence of eosinophilic inflammation (ie, high pretreatment eosinop

215 oteases as adjuvants developed predominantly eosinophilic inflammation and AHR.

216 n the lung that is accompanied by diminished eosinophilic inflammation and airway hyperresponsiveness

217 ce generated a similar phenotype of enhanced eosinophilic inflammation and allergic sensitization.

218 L-6, TNF-alpha, and IL-17 in contrast to the eosinophilic inflammation and IL-4 production observed i

219 TH2-driven eosinophilic inflammation and neutrophil-associated infl

220 designed to assess lebrikizumab's effect on eosinophilic inflammation and remodelling.

221 MCs and their products in driving the severe eosinophilic inflammation and respiratory dysfunction th

222 tics with a correlation between the baseline eosinophilic inflammation and the change in FEV1 .

223 While eosinophilic inflammation caused by type 2 cytokines is

224 tics had a lower FEV1 and Pc20 and increased eosinophilic inflammation compared to healthy subjects.

225 Longitudinal eosinophilic inflammation during treatment demonstrated

226 as a therapeutic strategy for management of eosinophilic inflammation in allergic airway disease, in

227 such, biomarkers currently used to delineate eosinophilic inflammation in asthmatic subjects should b

228 Clinical trials targeting eosinophilic inflammation in COPD should consider assess

229 genes associated with airway remodeling and eosinophilic inflammation in patients with asthma.

230 c inflammation in CRSwNP and its relation to eosinophilic inflammation in severe type 2 immune reacti

231 dy levels, but type 2 cytokine responses and eosinophilic inflammation in the airways remained unaffe

232 nd specific signaling pathways that regulate eosinophilic inflammation is critical for development of

233 oids, confirming the importance of measuring eosinophilic inflammation to guide corticosteroid use.

234 Only baseline eosinophilic inflammation was associated with the physio

235 Eosinophilic and mixed neutrophilic/eosinophilic inflammation were more prevalent in patient

236 attenuates airway hyperresponsiveness (AHR), eosinophilic inflammation, and mucus-production response

237 males with severe airflow limitation, little eosinophilic inflammation, and the least CS responsivene

238 signaling in asthma has been associated with eosinophilic inflammation, but little is known about the

239 in blocking antibodies reduced IL-33-induced eosinophilic inflammation, mucus metaplasia, and type 2

240 tes to lung ILC2 accumulation and downstream eosinophilic inflammation, mucus metaplasia, and type 2

241 In contrast to eosinophilic inflammation, neutrophilic inflammation was

242 f N-ERD, with skewing toward T2 response and eosinophilic inflammation.

243 have unanticipated consequences and promote eosinophilic inflammation.

244 llergen challenge phase for neutrophilic and eosinophilic inflammation.

245 is characterized by IgE hyperproduction and eosinophilic inflammation.

246 esulted in the recurrence of symptoms due to eosinophilic inflammation.

247 of the key type-2 cytokine pathways driving eosinophilic inflammation.

248 )-mediated potentiation of ovalbumin-induced eosinophilic inflammation; recruitment of platelet-adher

249 which may sustain inflammation that follows eosinophilic inflammatory processes.

250 g neurodegenerative disease characterized by eosinophilic intranuclear inclusions in the nervous syst

251 d diagnostic criteria of both PV and chronic eosinophilic leukemia (CEL).

252 The diagnosis chronic eosinophilic leukemia, not otherwise specified (CEL, NOS

253 Eosinophilic leukocytes develop in the bone marrow and m

254 mation after allergen exposure, with massive eosinophilic lung infiltrates and increased Th2 cytokine

255 6 receptors before sensitization exacerbated eosinophilic lung inflammation and type 2 cytokine produ

256 pates in the progression of allergen-induced eosinophilic lung inflammation to corticosteroid-refract

257 e lacking PTX3 have exaggerated neutrophilic/eosinophilic lung inflammation, mucus production, and ai

258 c), or the rat lungworm, is a major cause of eosinophilic meningitis.

259 t phenotypes of allergic airway inflammation-eosinophilic, mixed, and neutrophilic asthma via differe

260 (60.0-85.5) vs 80.5 (69.7-95.0), P=.009] for eosinophilic, mixed, neutrophilic and paucigranulocytic

261 Eosinophilic myocarditis (EM) is an acute life-threateni

262 in hypereosinophilic IL-5Tg mice resulted in eosinophilic myocarditis with severe ventricular and atr

263 s had moderate performance in distinguishing eosinophilic N-ERD (for blood eosinophils, AUC = 0.72; f

264 in and CCL26 were significantly increased in eosinophilic N-ERD and correlated with T2 signature in B

265 rmined in 167 participants and classified as eosinophilic (n = 84), neutrophilic (n = 14), paucigranu

266 granulocytic (n = 60), or mixed neutrophilic-eosinophilic (n = 9) asthma phenotypes.

267 Patients with eosinophilic nasal polyposis frequently require surgery,

268 cerbating inflammatory end points, including eosinophilic, neutrophilic, and ST2(+)CD4(+) T-cell infi

269 ma phenotypes: eosinophilic allergic asthma, eosinophilic nonallergic asthma and noneosinophilic nona

270 (CRSsNP, n = 86), and CRS with nasal polyps (eosinophilic NP: ENP, n = 81; non-eosinophilic NP: NENP,

271 al polyps (eosinophilic NP: ENP, n = 81; non-eosinophilic NP: NENP, n = 113) were enrolled in this st

272 Eosinophilic oesophagitis (EoE) is a chronic disease ass

273 Eosinophilic oesophagitis (EoE) is caused by the ingesti

274 Exclusion criteria included eosinophilic oesophagitis and severe asthma.

275 d protein-induced allergic proctocolitis and eosinophilic oesophagitis, is not well understood, leadi

276 lung (asthma), skin (eczema) or oesophagus (eosinophilic oesophagitis; EoE) and cancer at the organ

277 ardinal features of asthma in the absence of eosinophilic or neutrophilic inflammation.

278 e to corticosteroids, irrespective of airway eosinophilic or type 2 inflammation.

279 lar (P = .005) in neutrophilic compared with eosinophilic participants.

280 to the steroid-unresponsive nature of these eosinophilic patients.

281 dified intention-to-treat population with an eosinophilic phenotype were stratified according to bloo

282 ted in the recognition of an allergic and an eosinophilic phenotype, which are not mutually exclusive

283 than placebo among patients with COPD and an eosinophilic phenotype.

284 common forms of lung injury, including acute eosinophilic pneumonia and diffuse alveolar hemorrhage,

285 rances include organizing pneumonia or acute eosinophilic pneumonia patterns, the latter consisting o

286 We report the development of eosinophilic polyangiitis granulomatosis (EGPA) in a you

287 ults suggest that T1 (CXCL9 and CXCL10), T2 (eosinophilic proteins and CCL26), and T3 (CSF3) endotypi

288 d Ccr5, which together control monocytic and eosinophilic recruitment to resting and inflamed sites.

289 -33, group 2 innate lymphoid cell (ILC2) and eosinophilic responses to Alternaria allergen administra

290 aria allergen administration, and diminished eosinophilic responses to Nippostrongylus brasiliensis,

291 IL1RL1 gene expression is associated with eosinophilic SA, whereas NLRP3 inflammasome expression i

292 apies such as severe allergic and refractory eosinophilic severe asthma, while in other inflammatory

293 Tissue samples of patients with eosinophilic skin diseases or eosinophilic esophagitis w

294 n showed Periodic acid Schiff (PAS)-positive eosinophilic structures inside macrophages.

295 ure of BALF cells was more pronounced in the eosinophilic subphenotype of N-ERD.

296 rogrammed to skew allergic inflammation from eosinophilic T helper cell 2 (TH2) to neutrophilic TH17

297 processes, notably for this review involving eosinophilic tissue inflammation, such as eosinophilic e

298 rophilic inflammation associated with severe eosinophilic type 2 inflammatory CRSwNP, the role of whi

299 hilic granulomatosis with polyangiitis is an eosinophilic vasculitis.

300 and quantitative computed tomography between eosinophilic versus noneosinophilic COPD cases.